following a full submission:
garadacimab (Andembry®) is accepted for use within NHSScotland.
Indication under review: for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.
A double-blind, phase III study demonstrated that garadacimab significantly reduced the number of HAE attacks per month compared with placebo. Indirect comparisons suggest that garadacimab may have at least similar efficacy to berotralstat, lanadelumab, and a plasma-derived intravenous C1 esterase inhibitor.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- garadacimab (Andembry)
- SMC ID:
- SMC2912
- Indication:
Routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.
- Pharmaceutical company
- CSL Behring
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 November 2026